Turn Therapeutics(NASDAQ) TTRX

Turn Therapeutics Inc. creates skin and nail treatments for painful conditions.

The company makes special creams and gauze to help heal wounds.

Its newest products aim to stop itching without using pills.

Healing Skin and Nails

• GX-03 for Eczema: Lead drug candidate used to treat atopic dermatitis, which is a condition causing dry and itchy skin.
• Nail Fungus Therapy: Investigational treatment designed to penetrate nail plates to kill fungal infections.
• Wound Care Devices: Medical products cleared for managing sudden injuries and long-term skin sores.
• Medline Licensed Gauze: Antimicrobial material used to protect skin and prevent bacterial growth.

Strategic Deals and Trials

• Licensed the K183681 antimicrobial gauze to Medline Industries for supply and distribution.
• Expanded a Phase 2 clinical trial for its lead drug in June 2026 to include more patients.
• Signed a loan agreement with Avenue Capital in March 2026 for up to $25 million.
• Planned a new study for chronic skin inflammation to begin in mid-2027.

Local Treatments for Better Results

The company uses a delivery system that helps medication pass through thick skin and nails. This allows treatments to work directly on the affected area without the side effects of drugs that affect the whole body.

A Look at the Numbers

• Cash and cash equivalents totaled $10.3 million as of June 30, 2026.
• Net loss was $6.8 million for the six months ended June 30, 2026, compared to $1.6 million for the same period in 2025.
• Research and development expenses rose to $0.6 million for the six-month period ended June 30, 2026.
• The company reported zero revenue for the six months ended June 30, 2026.
• Management expects available cash to fund operations into the third quarter of 2027.

The Road Ahead

Turn Therapeutics has shifted its focus from basic medical devices to advanced medications for skin diseases. Its future depends on the successful testing and regulatory approval of its lead drug candidates.